Regulatory compliance – Page 44

Unsecured raw data storage during data review – preventing escalation to warning letter

“`html Mitigating Risks of Unsecured Raw Data Storage during Data Review in Pharma Unsecured raw data storage during data review can lead to significant compliance risks, potentially escalating into regulatory…

Audit findings repeat during routine operations – CAPA governance model

Tackling Recurring Audit Findings During Routine Operations: A Comprehensive CAPA Governance Model Recurring audit findings can be a significant challenge for pharmaceutical organizations, indicating potential weaknesses in processes or compliance.…

Repeat data integrity lapses during internal audit – CAPA effectiveness checks

“`html Addressing Recurring Data Integrity Issues Identified During Internal Audits In the highly regulated pharmaceutical environment, repeat data integrity lapses during internal audits can severely undermine confidence in the Quality…

Fragmented QMS processes during integration of new sites – metrics inspectors question

Managing Fragmented QMS Processes in New Site Integrations In the rapidly evolving landscape of pharmaceutical manufacturing, organizations often face the challenge of integrating new sites into existing Quality Management Systems…

Unsecured raw data storage during laboratory walkthrough – CAPA effectiveness checks

Addressing Unsecured Raw Data Storage During Laboratory Walkthroughs: An Effective CAPA Playbook Laboratories often face challenges related to data integrity, particularly concerning the storage of raw data. Unsecured raw data…

Ineffective deviation management during inspection readiness – CAPA governance model

Effective Solutions for Managing Deviations to Enhance Inspection Readiness In the pharmaceutical manufacturing landscape, ineffective deviation management can lead to significant risks during inspections and inquiries by regulatory authorities. Failure…

Unsecured raw data storage during FDA inspection – 483 risk assessment

Addressing Risks of Unsecured Raw Data Storage During FDA Inspections In pharmaceutical manufacturing, data integrity is essential to ensure product safety and regulatory compliance. One key concern arises when raw…

Poor QMS metrics during management review – regulatory expectations for QMS

Addressing Poor QMS Metrics During Management Review: A Comprehensive Playbook In the pharmaceutical industry, maintaining an effective Quality Management System (QMS) is non-negotiable. Yet, organizations often face challenges with poor…

Inadequate DI governance during laboratory walkthrough – evidence package for inspectors

Actionable Playbook for Addressing Insufficient Data Integrity Governance in Laboratory Walkthroughs Inadequate data integrity (DI) governance can significantly impact laboratory operations, leading to potential compliance issues during regulatory inspections. This…

Tag: Regulatory compliance